SRR1313172
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.440
- HEDGEHOG_SIGNALING+0.380
- MYOGENESIS+0.370
- UV_RESPONSE_DN+0.340
- WNT_BETA_CATENIN_SIGNALING+0.270
- KRAS_SIGNALING_UP+0.210
- TGF_BETA_SIGNALING+0.210
- APICAL_JUNCTION+0.190
- COAGULATION+0.190
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.170
Top 10 suppressed
- E2F_TARGETS-0.640
- MYC_TARGETS_V2-0.610
- G2M_CHECKPOINT-0.600
- MTORC1_SIGNALING-0.600
- MYC_TARGETS_V1-0.590
- OXIDATIVE_PHOSPHORYLATION-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.510
- GLYCOLYSIS-0.440
- DNA_REPAIR-0.430
- CHOLESTEROL_HOMEOSTASIS-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617871 | — | C | 0.920 |
| 2 | SRR8613705 | — | A | 0.912 |
| 3 | SRR11296806 | — | — | 0.894 |
| 4 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.891 |
| 5 | d7bbb44a-3fe0-4455-99d0-90be213f2a31 | — | — | 0.887 |
| 6 | SRR33346962 | — | — | 0.886 |
| 7 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.882 |
| 8 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.882 |
| 9 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.882 |
| 10 | 6b32f047-89ca-40e7-950f-a03493ea90c7 | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.440 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |